Sharp Therapeutics Corp.

As of December 31, 2025, Sharp Therapeutics Corp. carries a market capitalization of 55.04M, placing it among publicly traded companies globally. Its enterprise value stands at 55.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, Sharp Therapeutics Corp. has 30.08M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Sharp Therapeutics Corp. maintains a current ratio of 1.06, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -726.25, indicating conservative leverage, while an interest coverage ratio of -32.44 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -189.80, reflecting losses generated across the asset base.

As of the close on September 15, 2026, Sharp Therapeutics Corp.'s stock has gained approximately 25.00% over the past 52 weeks.

Over the twelve months ended December 31, 2025, Sharp Therapeutics Corp. generated - - in revenue and converted that into -6.17M in net income, yielding earnings per share of -0.21. EBITDA reached -5.41M, while operating income came in at -5.52M.

As of December 31, 2025, Sharp Therapeutics Corp. holds 956,596.00 in cash and equivalents against 1.28M in total debt, resulting in a net debt position of -956,596.00. Total book value stands at -176,595.00, with working capital of 60,595.00 providing operational flexibility.

Sharp Therapeutics Corp. produced -4.83M in operating cash flow over the twelve months ended December 31, 2025. After subtracting - - in capital expenditures, free cash flow totaled -4.83M - equivalent to -0.16 per share.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -8.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.22, meaning Sharp Therapeutics Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Sharp Therapeutics Corp.'s most recent stock split took place on January 27, 2025 with a 10:1 split ratio.

As of December 31, 2025, Sharp Therapeutics Corp. has an Altman Z-Score of -12.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.